2,775 reports of this reaction
8.8% of all BENRALIZUMAB reports
#1 most reported adverse reaction
ASTHMA is the #1 most commonly reported adverse reaction for BENRALIZUMAB, manufactured by AstraZeneca Pharmaceuticals LP. There are 2,775 FDA adverse event reports linking BENRALIZUMAB to ASTHMA. This represents approximately 8.8% of all 31,657 adverse event reports for this drug.
Patients taking BENRALIZUMAB who experience asthma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ASTHMA is moderately reported among BENRALIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to asthma, the following adverse reactions have been reported for BENRALIZUMAB:
The following drugs have also been linked to asthma in FDA adverse event reports:
ASTHMA has been reported as an adverse event in 2,775 FDA reports for BENRALIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ASTHMA accounts for approximately 8.8% of all adverse event reports for BENRALIZUMAB, making it one of the most commonly reported side effect.
If you experience asthma while taking BENRALIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.